Skip to content

Eagle Pharma heat stroke treatment rejected by FDA

July 26, 2017

Eagle Pharmaceuticals Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its drug Ryanodex to treat heat stroke and requested an additional clinical trial.

The drug, which is approved for the treatment and prevention of malignant hyperthermia, is being tested to treat exertional heat stroke (EHS), in conjunction with external cooling methods.

EHS is a severe form of heat-related illness that can be life-threatening.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: